Jayme Montgomery
Payments from drug & device makers
Across 47 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$217
- BD$211
- Johnson & Johnson$63
- Novo Nordisk$40
- Pfizer$36
- Supernus Pharmaceuticals, Inc.$36
- plus $171 from 8 others
What the payments were for
- Speaking & faculty fees$21127%
- Food & beverage$56373%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $217 |
| BD | 2 | $211 |
| Johnson & Johnson | 5 | $63 |
| Novo Nordisk | 3 | $40 |
| Pfizer | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Althera Pharmaceuticals LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$774 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $752 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $560 |
| Omeprazole | 25 | $508 |
| Hydroxyzine Hcl | 21 | $424 |
| Fluticasone Propionate | 25 | $350 |
| Atorvastatin Calcium | 28 | $215 |
| Cephalexin | 15 | $212 |
| Lisinopril | 53 | $211 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 12 | $167 |
| Estradiol | 18 | $165 |
| Gabapentin | 16 | $162 |
| Amlodipine Besylate | 25 | $147 |
| Levothyroxine Sodium | 20 | $144 |
| Rosuvastatin Calcium | 18 | $124 |
| Doxycycline Hyclate | 15 | $123 |
Paid to pharmacies, not to this prescriber.
Other family in Bixby
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Brandy ReevesNorman$17K
- Amanda OblanderYukon$17K
- Julia John SamuelOklahoma City$17K
- Jillian OakleafTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.